Zeynep Melekoglu Ellik

Zeynep Melekoglu Ellik

Auto-generated profile, based on publicly available information

Zeynep Melekoglu Ellik

Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
EÜEnver Üçbilek
Enver Üçbilek
AYAbdullah Emre Yıldırım
Abdullah Emre Yıldırım
ZEZeynep Ellik
Zeynep Ellik
ITİlKer Turan
İlKer Turan
BHBüşra Haktanıyan
Büşra Haktanıyan
RIRamazan Idilman
Ramazan Idilman
Background/Aims: The aim of our study was to investigate the underlying causes behind the etiology of cirrhosis in Türkiye. Materials and Methods: The study was comprised of patients with cirrhosis located in the gastroenterology clinics of 28 centers in Türkiye between January 2000 and June 2021. Results: The study group consisted of 4953 cirrhotic patients (median age: 62.2 years, male / female: 58% / 42%). Among the patients, 39% of the patients were compensated, and 61% were decompensated. Furthermore, 47.5% had Child-Pugh class A, 38% had ChildPugh class B, and 14.5% had Child-Pugh class C. The most frequent complaints were abdominal bloating (28%). Ascites (54.2%) was the most common manifestation of decompensation. The median Child-Pugh and MELD-Na scores were 7.0 and 10.0, respectively. The most common cause of cirrhosis was chronic viral hepatitis (43%), followed by cryptogenic cirrhosis (CC) (19%), metabolic dysfunction-associated steatotic liver disease (MASLD)-related cirrhosis (13%), and alcohol-related cirrhosis (11%). Among the 950 patients with CC, 416 had metabolic abnormalities. If these 416 CC patients with metabolic abnormalities were categorized as having MASLDrelated cirrhosis, the proportion of MASLD-related cirrhosis increased to 21%. Thirteen percent of the patients were diagnosed with HCC, while 4% had extrahepatic malignancy. Female breast cancer (18%) and colorectal cancer (18%) were the most frequent extrahepatic malignancies. Conclusion: Viral hepatitis remains the main cause of cirrhosis in Türkiye. However, its prevalence seems to be declining, whereas the prevalence of steatotic liver disease-related cirrhosis is increasing. Cite this article as: Üçbilek E, Yıldırım AE, Ellik Z, et al. Changing trends in the etiology of cirrhosis in Türkiye: A multicenter nationwide study. Turk J Gastroenterol. 2024;35(10):772-777.

1 January 2026 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
EBEmin Bodakci
Emin Bodakci
SKSaba Kiremitci
Saba Kiremitci
ZEZeynep Melekoglu Ellik
Zeynep Melekoglu Ellik
OKOzge Koc
Ozge Koc
MGMesut Gumussoy
Mesut Gumussoy
RIRamazan Idılman
Ramazan Idılman
Background and Aim: The present study aimed to determine the effect of hepatic steatosis, as detected by liver biopsy, on Hepatitis B surface antigen (HbsAg) seroclearance and disease progression in patients infected with hepatitis B virus (HBV). Materials and Methods: Patients with chronic HBV infection and chronic hepatitis B (CHB) from an existing cohort of HBV-infected patients were enrolled. Results: This study included 296 patients: 186 with chronic HBV in-fection and 110 with CHB. Patients with chronic HBV infection were older (p=0.006), and exhibited a higher prevalence of wild-type mutants (p

1 January 2024 in Hepatology Forum
Verified
Journal Article
Open access
MAMesut Akarsu
Mesut Akarsu
SDSüleyman DOLU
Süleyman DOLU
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
SYSezai Yilmaz
Sezai Yilmaz
MAMurat Akyildiz
Murat Akyildiz
RIRamazan Idilman
Ramazan Idilman
Background and Aim: This study aimed to identify the indications for liv-er transplantation (LT) based on underlying etiology and to characterize the patients who underwent LT. Materials and Methods: We conducted a multicenter crosssectional ob-servational study across 11 tertiary centers in Turkiye from 2010 to 2020. The study included 5,080 adult patients. Results: The mean age of patients was 50.3±15.2 years, with a predominance of female patients (70%). Chronic viral hepatitis (46%) was the leading etiological factor, with Hepatitis B virus infection at 35%, followed by cryptogenic cirrhosis (24%), Hepatitis C virus infection (8%), and al-cohol-related liver disease (ALD) (6%). Post-2015, there was a significant increase in both the number of liver transplants and the proportion of living donor liver transplants (p

1 January 2021 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
FKFatih Karakaya
Fatih Karakaya
SOSura Oztekin
Sura Oztekin
YOYelda Ozturk
Yelda Ozturk
CKCagdas Kalkan
Cagdas Kalkan
ZEZeynep Melekoglu Ellik
Zeynep Melekoglu Ellik
RIRamazan Idilman
Ramazan Idilman
Background and Aim: This study aimed to determine the presence of concomitant extrahepatic autoimmune disease (EAD) in patients with autoimmune liver disease (ALD) and the efficacy of the treatment response of ALD with the presence of any EAD. Materials and Methods: Between January 2001 and November 2017, 241 patients with ALD were included in the study. Results: Of the 241 patients, 88, 134, and 19 had autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and overlap syndrome (OS), respectively. Thirty-one patients had cirrhosis: 77% and 23% had compensated and decompensated disease, respectively. The presence of at least one EAD was defined in 38.6% of the patients with ALD (n=93), and 12% of them had ≥1 EAD. EAD was most commonly seen in patients with OS and PBC compared with those with AIH (p=0.036). Autoimmune thyroid disease was the most common association (20%), followed by Sjogren syndrome (12.0%). At the end of the follow-up period, 165 patients (72%) had biochemical response. The presence of EAD did not affect the biochemical response. Conclusion: EAD is most frequently seen in patients with ALD. The presence of EAD is not associated with the treatment response.

15 February 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
ZEZeynep Melekoglu Ellik
Zeynep Melekoglu Ellik
IIIlkay Idilman
Ilkay Idilman
AKAysun Kartal
Aysun Kartal
HBhatice yasemin Balaban
hatice yasemin Balaban
AEAtilla Halil Elhan
Atilla Halil Elhan
RIRamazan Idilman
Ramazan Idilman
Background: Liver graft fibrosis affects long-term graft and patient survival in liver transplant recipients. Transient elastography and magnetic resonance elastography are widely used for the assessment of liver fibrosis in routine clinical practice, but are limited in liver transplant settings. The aims of the present study were to evaluate the accuracy of magnetic resonance elastography and transient elastograph in the assessment of liver fibrosis in liver transplant recipients, and to determine the recurrence rates of post-transplant hepatic steatosis and liver fibrosis. Methods: A total of 126 consecutive liver transplant recipients were included. Magnetic resonance elastography and transient elastography were performed for to measure liver stiffness. Results: The most common cause of liver transplantation was hepatitis B virus-induced cirrhosis (50%). The mean liver stiffness value with transient elastography was 6.1 ± 3.0 kPa, and the mean magnetic resonance elastography value was 2.7 ± 1.0 kPa. A significant positive correlation was found between magnetic resonance elastography and transient elastography in terms of liver stiffness measurement (r = 0.61, P < .001). Obesity and the underlying etiology of liver diseases did not have any significant negative effect on magnetic resonance elastography and transient elastography measurements. During the follow-up, the post-transplant recurrence rates of hepatic steatosis and hepatic fibrosis were 26% and 37%, respectively. The recurrence rates of post-transplant hepatic steatosis and liver fibrosis were slightly higher in recipients with non-alcoholic fatty liver disease-related cirrhosis than those with viral hepatitisrelated etiologies (44% vs 27%, P = .43; 44% vs 30%, P = .45, respectively). Conclusion: Magnetic resonance elastography and transient elastography are accurate in assessing liver fibrosis in the liver transplant setting. Obesity and the underlying etiology of primary liver disease do not influence the measurements.

15 August 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
MÖMübin Özercan
Mübin Özercan
ZEZeynep Melekoğlu Ellik
Zeynep Melekoğlu Ellik
APAyhan Parmaksız
Ayhan Parmaksız
MGMesut Gümüşsoy
Mesut Gümüşsoy
SDSerkan Duman
Serkan Duman
NÖNecati Örmeci
Necati Örmeci
Background/Aims: The presence of liver fibrosis is the most important indicator of progression to cirrhosis. Noninvasive measurement of liver stiffness is crucial for detecting fibrosis. Vibration-controlled transient elastography is one of the most useful methods for this purpose. We aimed to compare the liver stiffness and steatosis measurements with iLivTouch© and the FibroScan© elastography devices Materials and Methods: Two hundred thirty-seven consecutive adult patients with chronic hepatitis were included in the study. The liver stiffness and steatosis were measured with iLivTouch and FibroScan on the same day. Thirty-one patients had liver biopsies on the same day with elastography procedures. The diagnostic performances of iLivTouch and FibroScan were compared to aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). Results: The liver stiffness measurements obtained using iLivTouch and FibroScan had median value of 10.3 (ranging from 2.9 to 46.3) and 7.2 (ranging from 2.5 to 75), respectively. The mean steatosis measurements using ultrasound attenuation parameter with iLivTouch were 245.51 ± 45.79, while the mean controlled attenuation parameter measurements using FibroScan were 259.37 ± 75.0. In subgroup analysis, the AUC of iLivTouch on detecting signiicant fibrosis [0.83, (P = .002)] was minimally higher than other noninvasive methods [0.82 for NFS (P = .003), 0.80 for FibroScan (P = .006), 0.68 for FIB-4 (P = .089), and 0.53 for APRI (P = .76)]. Conclusion: The stiffness and steatosis measurements with iLivTouch and FibroScan were not similar. The accuracy of iLivTouch in detecting significant and advanced fibrosis was minimally higher. Large clinical trials are necessary to support these findings. Cite this article as: Özercan M, Melekoğlu Ellik Z, Parmaksız A, Gümüşsoy M, Duman S, Örmeci N. Liver stiffness and steatosis measurements with iLivTouch and FibroScan: A comparative study. Turk J Gastroenterol. 2024;35(8):634-642.